Cargando…

Adalimumab treatment in Crohn’s disease: an overview of long-term efficacy and safety in light of the EXTEND trial

The advent of anti-tumor necrosis factor (TNF) therapies revolutionized the treatment of inflammatory bowel disease. Adalimumab is a subcutaneous anti-TNF agent indicated for use in patients with moderate-to-severe Crohn’s disease and those with moderate-to-severe ulcerative colitis. In both disease...

Descripción completa

Detalles Bibliográficos
Autores principales:	Asgharpour, Amon, Cheng, Jianfeng, Bickston, Stephen J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3770493/ https://www.ncbi.nlm.nih.gov/pubmed/24039442 http://dx.doi.org/10.2147/CEG.S35163

Ejemplares similares

Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease
por: Faubion, William A., et al.
Publicado: (2017)

Efficacy of Adalimumab in Korean Patients with Crohn’s Disease
por: Sohn, Il Woong, et al.
Publicado: (2016)

Adalimumab in Crohn’s disease
por: Van Assche, Gert, et al.
Publicado: (2007)

Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohn's Disease
por: Dubinsky, Marla C., et al.
Publicado: (2016)

Adalimumab for the treatment of Crohn’s disease
por: Cassinotti, Andrea, et al.
Publicado: (2008)

Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn’s Disease Studies
por: Panaccione, Remo, et al.
Publicado: (2019)

Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis
por: Yang, Hua-Hua, et al.
Publicado: (2022)

Long-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
por: Mizoshita, Tsutomu, et al.
Publicado: (2016)

Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn’s disease: results from a randomized trial
por: Chen, Baili, et al.
Publicado: (2020)

Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study
por: Hisamatsu, Tadakazu, et al.
Publicado: (2021)

Distinct alterations of fecal microbiota refer to the efficacy of adalimumab in Crohn’s disease
por: Chen, Liang, et al.
Publicado: (2022)

Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn's Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study
por: Chang, Chen-Wang, et al.
Publicado: (2014)

Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn’s Disease
por: Ogata, Haruhiko, et al.
Publicado: (2016)

Efficacy and safety of adalimumab in ankylosing spondylitis
por: Mounach, Aziza, et al.
Publicado: (2014)

Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis
por: Ruperto, N, et al.
Publicado: (2011)

Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study)
por: Narcisi, Alessandra, et al.
Publicado: (2020)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Management of Crohn’s disease in poor responders to adalimumab
por: de Boer, Nanne KH, et al.
Publicado: (2014)

Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn’s Disease: Results from the EXTEND Trial
por: Reinisch, Walter, et al.
Publicado: (2017)

Clinical efficacy of adalimumab in Crohn’s disease: a real practice observational study in Japan
por: Takeshima, Fuminao, et al.
Publicado: (2016)

Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease
por: Jung, Yoon Suk, et al.
Publicado: (2021)

A Meta-Analysis of Adalimumab for Fistula in Crohn's Disease
por: Fu, Yin-mei, et al.
Publicado: (2017)

Difficult-to-treat-pediatric Crohn’s disease: focus on adalimumab
por: Zeisler, Bella, et al.
Publicado: (2015)

Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn’s Disease
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2019)

Leukocytoclastic Vasculitis Associated with Adalimumab Therapy for Crohn’s Disease
por: Xu, Lankai Cathy, et al.
Publicado: (2023)

Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis
por: Kotaniemi, Kaisu, et al.
Publicado: (2011)

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy
por: Sandborn, W. J., et al.
Publicado: (2018)

T.06.4 LONG TERM EFFICACY AND SAFETY OF ABP 501 ADALIMUMAB BIOSIMILAR ON INFLAMMATORY BOWEL DIESASES: THE ADASWITCH STUDY
por: Cingolani, A., et al.
Publicado: (2022)

Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial
por: Inoue, Nagamu, et al.
Publicado: (2017)

Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn’s Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials
por: Panaccione, Remo, et al.
Publicado: (2018)

Long-term treatment of rheumatoid arthritis with adalimumab
por: Murdaca, Giuseppe, et al.
Publicado: (2013)

Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn’s Disease: Results of the PYRAMID Registry
por: Loftus, Edward V, et al.
Publicado: (2019)

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
por: Burmester, Gerd R, et al.
Publicado: (2013)

Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy
por: Colombel, J.‐F., et al.
Publicado: (2016)

Long-Term Efficacy of Adalimumab in Patients With Intestinal Behcet’s Disease: Eight Consecutive Cases
por: Tanida, Satoshi, et al.
Publicado: (2016)

Mesenteric Fibromatosis in Crohn's Disease as a Potential Effect of Adalimumab
por: Abdelqader, Abdelhai, et al.
Publicado: (2016)

Listeria Monocytogenes Brain Abscess in Crohn's Disease Treated with Adalimumab
por: Atsawarungruangkit, Amporn, et al.
Publicado: (2017)

Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
por: Im, Jong Pil
Publicado: (2017)

Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn's disease
por: Ji, Cheng-Chun, et al.
Publicado: (2017)

Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_djej75cb7b1e69rn1erlu9pjq4